641 related articles for article (PubMed ID: 16477217)
1. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
2. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
[TBL] [Abstract][Full Text] [Related]
3. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
4. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant diabetes mellitus: incidence and risk factors.
Mazali FC; Lalli CA; Alves-Filho G; Mazzali M
Transplant Proc; 2008 Apr; 40(3):764-6. PubMed ID: 18455010
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.
Cosio FG; Pesavento TE; Osei K; Henry ML; Ferguson RM
Kidney Int; 2001 Feb; 59(2):732-7. PubMed ID: 11168956
[TBL] [Abstract][Full Text] [Related]
10. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
11. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
12. Conversion therapy to everolimus in renal transplant recipients: results after one year.
Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy.
Sato T; Inagaki A; Uchida K; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Tominaga Y; Okajima Y; Ohta K; Suga H; Taguchi S; Kakiya S; Itatsu T; Kobayashi T; Nakao A
Transplantation; 2003 Nov; 76(9):1320-6. PubMed ID: 14627910
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
[TBL] [Abstract][Full Text] [Related]
15. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):252-8. PubMed ID: 14742990
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors.
Wyzgał J; Paczek L; Sańko-Resmer J; Ciszek M; Nowak M; Rowiński W; Szmidt J; Durlik M
Ann Transplant; 2007; 12(2):26-9. PubMed ID: 18173063
[TBL] [Abstract][Full Text] [Related]
18. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.
van den Hoogen MW; van der Hoeven AM; Hilbrands LB
Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus.
Numakura K; Satoh S; Tsuchiya N; Horikawa Y; Inoue T; Kakinuma H; Matsuura S; Saito M; Tada H; Suzuki T; Habuchi T
Transplantation; 2005 Nov; 80(10):1419-24. PubMed ID: 16340785
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors.
Ollech JE; Kramer MR; Peled N; Ollech A; Amital A; Medalion B; Saute M; Shitrit D
Eur J Cardiothorac Surg; 2008 May; 33(5):844-8. PubMed ID: 18339554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
